The estimated Net Worth of Eagle Investment Management... is at least $41.6 Миллион dollars as of 20 June 2019. Eagle Management owns over 4,000,000 units of Durect Corp stock worth over $41,568,177 and over the last 8 years Eagle sold DRRX stock worth over $0.
Eagle has made over 2 trades of the Durect Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently Eagle bought 4,000,000 units of DRRX stock worth $2,080,000 on 20 June 2019.
The largest trade Eagle's ever made was buying 4,000,000 units of Durect Corp stock on 20 June 2019 worth over $2,080,000. On average, Eagle trades about 2,047,500 units every 480 days since 2016. As of 20 June 2019 Eagle still owns at least 26,476,546 units of Durect Corp stock.
You can see the complete history of Eagle Management stock trades at the bottom of the page.
Over the last 21 years, insiders at Durect Corp have traded over $528,010 worth of Durect Corp stock and bought 19,954,650 units worth $23,296,708 . The most active insiders traders include April Fund Ltd21 April Fund..., Eagle Investment Management... и Felix Theeuwes. On average, Durect Corp executives and independent directors trade stock every 55 days with the average trade being worth of $468,485. The most recent stock trade was executed by Judith J. Robertson on 18 August 2022, trading 80,942 units of DRRX stock currently worth $68,801.
durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use
Durect Corp executives and other stock owners filed with the SEC include: